Format

Send to

Choose Destination
See comment in PubMed Commons below
World J Gastrointest Pharmacol Ther. 2012 Aug 6;3(4):68-73. doi: 10.4292/wjgpt.v3.i4.68.

Helicobacter pylori therapy: Present and future.

Author information

  • 1Vincenzo De Francesco, Enzo Ierardi, Gastroenterology Unit, Department of Medical Sciences, University of Foggia, Ospedali Riuniti, 71100 Foggia, Italy.

Abstract

Helicobacter pylori (H. pylori) plays a crucial role in the pathogenesis of chronic active gastritis, peptic ulcer and gastric mucosa-associated lymphoid tissue-lymphoma, and is also involved in carcinogenesis of the stomach. H. pylori treatment still remains a challenge for physicians, since no current first-line therapy is able to cure the infection in all treated patients. Several factors may help in the eradication of therapy failure. We reviewed both bacterial and host factors involved in therapeutic management of the H. pylori infection. In addition, we evaluated data on the most successful therapy regimens - sequential and concomitant therapies - currently available for H. pylori eradication.

KEYWORDS:

Antibiotic resistance; Eradication; Helicobacter pylori; Therapy; Virulence factors

PMID:
22966485
PMCID:
PMC3437448
DOI:
10.4292/wjgpt.v3.i4.68
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Support Center